Sanatorio de la Mujer | Sede Centro

Research site

(Unclaimed)

Location

San Luis 2493, Rosario, Santa Fe, Argentina

Site insights

Top conditions

Top treatments

Atezolizumab

Bevacizumab

Dexamethasone

Capecitabine

PF-06863135

TAR-210

Pembrolizumab

KRT-232

Pertuzumab

Tisotumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 17 total trials

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermed...

Enrolling

Myelofibrosis

Drug: Imetelstat

Drug: Best Available Therapy (BAT)

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Active, not recruiting

Atrial Fibrillation

Drug: Apixaban Placebo

Drug: Milvexian

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (MoonRISe-1)

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's ch...

Enrolling

Non-Muscle Invasive Bladder Cancer

Drug: Gemcitabine

Drug: MMC

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer (VERITAC-2)

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Active, not recruiting

Advanced Breast Cancer

Drug: ARV-471

Drug: Fulvestrant

Locations recently updated

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (MAGNETISMM-5)

The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multi...

Enrolling

Multiple Myeloma

Drug: Elranatamab

Drug: Pomalidomide

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer bene...

Enrolling

Post-Polycythemia Vera MF (Post-PV-MF)

Primary Myelofibrosis (PMF)

Drug: Best Available Therapy (BAT)

Drug: KRT-232

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as mainte...

Enrolling

Peritoneal Cancer

Fallopian Tube Cancer

Drug: Bevacizumab

Drug: Mirvetuximab soravtansine plus Bevacizumab

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5)

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemo...

Active, not recruiting

Ovarian Neoplasms

Fallopian Tube Adenocarcinoma

Drug: Paclitaxel

Biological: Placebo

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement (FOENIX-CCA4)

This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and eff...

Enrolling

FGFR2 Fusions

Advanced Cholangiocarcinoma

Drug: TAS-120

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's...

Active, not recruiting

Breast Neoplasms

Drug: dextrose

Drug: liposomal doxorubicin

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301)

This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cer...

Active, not recruiting

Cervical Cancer

Drug: topotecan

Drug: gemcitabine